摘要
目前以阿尔茨海默病(AD)主要病理特点——“β-淀粉样蛋白级联假说、tau蛋白异常聚集”为靶点研发的多种药物,疗效都不理想。随着对AD病理机制的研究进展,小胶质细胞及其相关表达基因TREM2、CD33、ABCA7和与其相关的信号传导通路在AD病理机制中的作用越来越被重视,基于小胶质细胞及其相关表达基因的AD生物学标志物和治疗靶点的研究也明显增多。文中将对小胶质细胞的病理生理、小胶质细胞在AD中的作用机制和小胶质细胞相关的生物学标志物、AD药物治疗进行简要综述。
At present,many drugs were developed based on the main pathological feature of Alzheimer′s disease(AD):"β-amyloid cascade hypothesis and abnormal tau protein aggregation"as targets,but the efficacy is unsatisfactory.With the progress on the study of pathological mechanism of AD,the role of microglia and their related expression genes,such as TREM2,CD33,ABCA7 gene and their related signal transduction pathways in the pathological mechanism of AD has been paid more and more attention.The study on AD biomarkers and therapeutic targets based on microglia and their related expression genes has also increased significantly.This review will mainly focus on the pathophysiology of microglia,the mechanism of microglia in AD,the biomarkers related to microglia and the drug treatment of AD.
作者
肖向荣
李若林
郝延磊
Xiao Xiangrong;Li Ruolin;Hao Yanlei(Cheeloo College of Medicine,Shandong University,Jinan 250012,China;Department of Neurology,Affiliated Hospital of Jining Medical University,Jining 272000,China)
出处
《中华神经科杂志》
CAS
CSCD
北大核心
2022年第5期520-524,共5页
Chinese Journal of Neurology
基金
国家自然科学基金(81771360)。
